Pfizer's Ibrance Fails To Significantly Extend Survival In Breast Cancer Study

10:09 EDT 26 Jun 2018 | Pharmaceutical Processing

News

Pfizer's breast cancer drug combo falls short of survival goal/

Contributed Author:

Reuters

Topics:

More From BioPortfolio on "Pfizer's Ibrance Fails To Significantly Extend Survival In Breast Cancer Study"